Abstract

Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a checklist of information to include in publications describing in vivo experiments to enable others to scrutinise the work adequately, evaluate its methodological rigour, and reproduce the methods and results. Despite considerable levels of endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent, and the anticipated improvements in the quality of reporting in animal research publications have not been achieved. Here, we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to facilitate their use in practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into 2 sets, the “ARRIVE Essential 10,” which constitutes the minimum requirement, and the “Recommended Set,” which describes the research context. This division facilitates improved reporting of animal research by supporting a stepwise approach to implementation. This helps journal editors and reviewers verify that the most important items are being reported in manuscripts. We have also developed the accompanying Explanation and Elaboration document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to clarify key concepts, and (3) to provide illustrative examples. We aim, through these changes, to help ensure that researchers, reviewers, and journal editors are better equipped to improve the rigour and transparency of the scientific process and thus reproducibility.

Highlights

  • Endorsement typically includes advocating their use in guidance to authors and reviewers. Despite this level of support, recent studies have shown that important information as set out in the Animal Research (ARRIVE) guidelines is still missing from most publications sampled

  • Transparent reporting is clearly essential if animal studies are to add to the knowledge base and inform future research, policy, and clinical practice

  • ARRIVE 2.0 prioritises the reporting of information related to study reliability. This enables research users to assess how much weight to ascribe to the findings and, in parallel, promotes the use of rigorous methodology in the planning and conduct of in vivo experiments [37], increasing the likelihood that the findings are reliable and, reproducible

Read more

Summary

Study design

Specify the exact number of experimental units allocated to each group, and the total number in each experiment. Provide details of any a priori sample size calculation, if done. Describe any criteria used for including and excluding animals (or experimental units) during the experiment, and data points during the analysis. Specify if these criteria were established a priori. B. For each experimental group, report any animals, experimental units, or data points not included in the analysis and explain why. State whether randomisation was used to allocate experimental units to control and treatment groups. Provide details of the statistical methods used for each analysis, including software used. Provide further relevant information on the provenance of animals, health/immune status, genetic modification status, genotype, and any previous procedures

Results
Background
Ethical statement
Declaration of interests
Findings
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.